BiotechTubeBiotechTube
Home/Pipeline/Orforglipron

Orforglipron

Type 2 Diabetes

Phase 3Active

Key Facts

Indication
Type 2 Diabetes
Phase
Phase 3
Status
Active
Company
Eli Lilly

About Eli Lilly

Eli Lilly is one of the world's largest pharmaceutical companies with over 145 years of experience in developing life-changing medicines. The company has achieved significant recent success with GLP-1 receptor agonists for diabetes and weight management, generating substantial revenue growth. Lilly continues to invest heavily in R&D across key therapeutic areas including diabetes, oncology, autoimmune diseases, and neurodegeneration, with a robust pipeline of innovative treatments in development.

View full company profile

Therapeutic Areas

DiabetesOncologyImmunologyNeuroscienceObesityCardiovascular

Other Type 2 Diabetes Drugs

DrugCompanyPhase
Tirzepatide (Mounjaro)Eli LillyApproved
Trulicity (dulaglutide)Eli LillyApproved
ForxigaAstraZenecaApproved
siRNA GalXC-GYS2Novo NordiskPhase 1
Amylin/semaglutide combinationNovo NordiskPhase 3
LipaglynZydus LifesciencesApproved
LBS-009Belite BioPreclinical
Jentadueto (Linagliptin/Metformin)YuhanApproved
Nesina (Alogliptin)YuhanApproved
Metformin & CombinationsIpca LaboratoriesCommercial
GSBR-1290Structure TherapeuticsPhase 2
MetforminGranules IndiaApproved/Commercial